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Objectives: Invasive prenatal procedures including amniocentesis, chorionic villus sampling
(CVS)  can  be  prenatally  indicated  for  diagnostic  purposes.  Chronic  viral  infections  with
Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) are
not uncommon in women of reproductive age. 
The aim of this narrative literature review is to provide guidance on the best clinical practice
in antenatal invasive testing and fetal surveillance in pregnancies with HIV, HCV, HBV and
treponema pallidum infected women. 
Material and methods: A review of the literature was conducted in the database of PubMed
to select full-length articles published in peer-reviewed journals between 1990 and 2020. The
keywords along with respective combinations included in the search strategy were invasive
testing,  prenatal  diagnosis,  amniocentesis,  chorionic  villus  sampling,  cordocentesis,
fetoscopy,  chronic  viral  infections,  hepatitis  B,  hepatitis  C,  HIV,  treponema  pallidum,
syphilis, vertical transmission, MTCT.
Results: For patients with hepatitis B infection, it is important to assess the HBeAg status and
HBV DNA levels and for those patients with high viral load, antiviral therapy (Tenofovir) for
a few weeks may be needed to reduce the viral  load  prior  to  the invasive  procedure.  In
women positive for HCV, the viral load and HIV status should be assessed to establish the
risk of vertical transmission; while for patients with HIV, highly active antiretroviral therapy
administration and low viral load are predictive for reduced vertical transmission even after
performing an invasive procedure. In all cases invasive procedure should be replaced by non-
invasive prenatal testing if this is a feasible alternative and when invasive testing is indeed
required, transplacental passage should be avoided. 
Key words: invasive testing, vertical transmission, hepatitis B, hepatitis C, HIV, treponema
pallidum
INTRODUCTION
Invasive  prenatal  procedures  including  amniocentesis,  chorionic  villus  sampling
(CVS), cordocentesis can be prenatally indicated for diagnosis or therapeutic purposes. The
main  concern  related  to  invasive  procedures  in  pregnancy  is  the  risk  of  miscarriage  or
preterm birth,  risk which was extensively studied in large observational  studies [1]. Fetal
medicine specialists should also be aware of other potential risks, such as possible increased
rate  of vertical  transmission of chronic infections  or isoimmunization  in  Rhesus negative
patients. Therefore, pregnant women should be properly counselled before consenting for an
invasive  procedure.  With  the  new  development  of  more  accurate  screening  methods,  an
invasive  testing  is  nowadays  offered  with  precaution.  If  in  the  past  one  of  the  main
indications for performing an invasive testing was advanced maternal age, the non-invasive
prenatal testing through cell-free DNA (cfDNA) has now replaced most of these unnecessary
invasive procedures  in high-risk patients  based only on maternal  age or previous history.
Moreover,  new technologies  are  being  developed  to  screen  general  population  for  other
genetic disorders besides the commonest chromosomal abnormalities. Single-gene diseases
and  fetal  exome  sequencing  are  the  new  target  of  cell  free  DNA technique,  but  the
performance of such test in screening for such rare genetic disorders is yet to be established
[2].  Currently,  the most  common indications  for diagnostic  invasive testing are abnormal
screening test results [3], structural abnormalities identified by ultrasound, familial genetic
disorders with recurrence risks, while for the therapeutic purpose, an invasive procedure is
most frequently performed in cases of fetal anemia for intrauterine blood transfusion.  
Chronic  viral  infections  with  Human  Immunodeficiency  Virus  (HIV),  hepatitis  C
virus (HCV), hepatitis B virus (HBV) are not uncommon in women of reproductive age and
general efforts have been made to develop best strategies on how to manage pregnancy and
delivery in these women to prevent vertical transmission and to reduce perinatal morbidity.
Routine  antenatal  screening  for  maternal  viral  infections,  antiviral  treatment  throughout
pregnancy,  early  postpartum  vaccination  and  immunoglobulin  administration  or  neonatal
treatment are current recommendations proven to be beneficial in reducing the mother-to-
child-transmission (MTCT). In addition to these active therapeutic measures, avoiding some
invasive  procedures  during  pregnancy or  delivery,  procedures  that  might  cause  placental
disruption,  increasing  the  maternal-fetal  blood  contamination  and  thereby  to  possibly
increasing  viral  transmission,  has  been considered  protective.  The real  effect  of  invasive
prenatal  procedure  on  vertical  transmission  rate  is  not  completely  understood,  but  the
potential risks derived from current data should not be ignored and should be discussed with
the parents prior to an invasive testing. 
The overall  aim of this narrative literature review is to provide guidance on the best
clinical practice in antenatal invasive testing and fetal surveillance in pregnancies with HIV,
HCV, HBV or Treponema Pallidum infected women. Vertical transmission or MTCT defines
the transmission of the virus from the mother to the unborn child during pregnancy, at the
time of delivery, or during the first six weeks postpartum.
MATERIAL AND METHODS
A review of the literature was conducted in the database of PubMed, to select full-
length articles published in peer-reviewed journals between 1990 and 2020. The keywords
along with respective  combinations  included in the search strategy were invasive testing,
prenatal  diagnosis,  amniocentesis,  chorionic  villus  sampling,  cordocentesis,  fetoscopy,
chronic viral infections, hepatitis B, hepatitis C, HIV, treponema pallidum, syphilis, vertical
transmission, MTCT.
Hepatitis B Virus 
Hepatitis B infection is a global health concern mostly because of its persistence as chronic
infection and potential risk of hepatocellular carcinoma. The earlier the infection is acquired
the  higher  the  risk  of  persisting  as  chronic  infection.  Up  to  90%  of  subjects  infected
perinatally may develop chronic infection and almost 30% will end up developing cirrhosis,
compared to a risk of less than 5% when infection occurs during adulthood [4]. Due to this
risk,  MTCT has  been  a  recent  subject  of  research  to  prevent  or  to  reduce  the  risk  of
transmission during pregnancy and childbirth. 
The  introduction  of  Hepatitis  B vaccine,  a  recombinant  vaccine,  has  dramatically
reduced the number of new cases of Hepatis B infection. More strategies are used to prevent
MTCT of  HBV infections,  such as  universal  screening for  maternal  hepatitis  B infection
(hepatitis B surface antigen (HBsAg)) at booking; hepatitis B vaccination during pregnancy
under specific circumstances (when the immunization series had begun before conception or
a previously unvaccinated, uninfected pregnant women is at increased risk for acquiring the
virus [5, 6]; hepatitis B immunoglobulin (HBIG 250IU) administrated to the neonate during
the first 24 hours of life when the mother has HBV infection (second dose at 4 weeks of age)
in addition to the universal vaccine (8, 12 and 16 weeks of age). These have contributed to a
reduction of 95 to 97% in MTCT rates [7]. Despite all these strategies, perinatal transmission
still represents almost 50% of all new HBV infections. 
Data regarding maternal-fetal transmission during pregnancy and delivery show that
this risk is related to hepatitis B e-antigen (HBeAg) status. When positive it indicates that the
virus  is  actively replicating  and therefore  the  person is  infectious  and can cause vertical
transmission. Low viral load (VL) of HBV DNA below 107 copies/mL (7.0 log10 copies/Ml)
and additionally passive immunization at birth, maternal antiviral therapy during pregnancy
can reduce the risk of transmission [8, 9]. 
There  are  contradictory  data  regarding  the  transmission  risk  after  an  invasive
procedure.  Most  of the studies  involved a  small  number  of  pregnancies,  incomplete  data
regarding the DNA HBV viral load or concomitant HBeAg status or inappropriate postpartum
follow up. The most likely route of transmission during an invasive procedure is by maternal
fetal blood contamination or amniotic fluid contamination, transplacental procedures caring a
significant higher risk of contamination [10]. Although very uncommon, other mechanism of
intrauterine transmission has been recently described in the early stage of pregnancy via an
infected male germline or maternal oocytes in the embryonic stage [11]. 
Contrary to what was previously reported,  the latest  data  coming from the largest
retrospective  study  involving  143  pregnancies  positive  for  hepatitis  B  undergoing
amniocentesis  between  16  and  35  weeks  gestation,  showed  that  an  invasive  procedure
increases the MTCT risk in HBsAg-positive pregnant women, and viral load HBV DNA ≥
107  copies/mL (7.0 log10 copies/mL). The MTCT rate was 2.5% in women who underwent
amniocentesis  vs  0.5%  in  patient  without  invasive  procedure  and  all  cases  of  vertical
transmission  were  in  patients  HBeAg  positive  [12].  However,  the  results  should  be
interpreted with caution, as the reported rate of vertical transmission in this cohort was much
lower than previously shown in HBeAg positive patients where the MTCT rate is about 5-
10% even in cases without an invasive procedure [13].  Moreover, the study results showed
that  antiviral  therapy  a  few  weeks  prior  to  invasive  testing  (Tenofovir,  Telbivuldine  or
Lamivudine) seems to reduce MTCT rates in mothers with high viral load (0% vs 14%) [12]. 
These  data  are  consistent  with  a  retrospective  study from 2014  which  also  showed  that
although  amniocentesis  did  not  increase  the  risk  of  MTCT in  the  general  cohort,  it  was
significantly associated with a higher rate of vertical transmission in the subgroup of women
with high HBV DNA levels, above 107 copies/mL (7.0 log10 copies/mL), with a transmission
rate of 50% in the group with amniocentesis vs. 4.5% in the non-invasive group. Placental
position  also  appears  to  be  an  independent  risk  factor,  as  all  infected  infants  in  the
amniocentesis group had an anterior placenta [10].  A summary of the studies is listed in
Table 1. 
These new results  suggest  that  amniocentesis  in  women with hepatitis  B, HBeAg
positive  or  with  high  viral  load  should  be  considered  in  highly  selected  cases  when the
suspected  genetic  conditions  are  beyond  the current  clinical  applicability  of  non-invasive
genetic testing and in those cases the antiviral therapy (Tenofovir) for a few weeks may be
needed to reduce the viral  load prior to the procedure [12].  Avoiding placenta is  another
important  measure  to  reduce  the  risk  of  vertical  transmission,  therefore  the  invasive
procedure in the first trimester through CVS should be postponed and replaced with second
trimester testing through amniocentesis. 
Currently there are no available  studies to report  on vertical  transmission of HBV
using other prenatal invasive procedures such as CVS, fetal blood sampling or therapeutic
invasive procedures, therefore the risks and benefits of such procedures should be assessed
and discussed with the parents prior to their clinical use.
Hepatitis B immunoprophylaxis failure occurs in 5-10% of infants of HBV-infected
mothers HBeAg-positive,  even without any invasive testing performed prenatally.  Various
factors have been reported in relation to immunoprophylaxis failure: earlier administration of
immunoglobulin and first dose of vaccine within 1-2 hours after birth instead of first 12-24 h
[18], HBV DNA levels, low birth weight or preterm infants. Administration of HBIG in the
third  trimester  of  pregnancy,  vaginal  delivery  and breastfeeding  did  not  seem to  have  a
significant effect on HBV mother-to-infant transmission [19]. 
Prenatal fetal contamination as a cause of postnatal immunoprophylaxis failure has
been studied through various fetal samples collected by prenatal invasive procedures, either
of amniotic fluid, fetal blood sample or placental tissue to assess the fetal intrauterine status
before  labour  and  to  determine  if  the  passive-active  immunoprophylaxis  administered
postpartum is ineffective due to early fetal intrauterine infection. In a study on more than 250
pregnant women with HBsAg positive invasive prenatal procedure was undertaken in 197 of
cases  of  amniocentesis  and 55 of  cordocentesis.  There  were 92 women also  positive  for
HBeAg and 146 had detectable levels of DNA HBV with a mean of 6.5 log10 copies/mL
(3,162,278 copies/mL). Low levels of HBV DNA were found in 12 amniotic fluid samples
and four  blood samples  and all  16 cases  of  HBV DNA-positive  fetuses  were limited  to
HBeAg-positive mothers with viral loads higher than 106 copies/mL. All neonates received
the  vaccine  at  birth  and  198  were  followed  up  at  one  year  of  life.  Despite
immunoprophylaxis,  there  were  six  children  with  persistent  positive  HBsAg,  all  born  to
HBeAg-positive mothers with high serous HBV DNA levels. Only one of them was found to
be  positive  for  intrauterine  HBV DNA and three  of  them were  found to  be  intrauterine
HBeAg positive.  The conclusion of the study was that prenatal  intrauterine expression of
HBV antigens  and HBV DNA does not necessarily indicate  postnatal  HBV infection and
vaccine failure [20]. Immature placenta might allow small quantities of soluble HBsAg and
free HBV DNA leakage into the uterus, but the hepatocytes are fully developed later in the
second half of pregnancy and only after that period are able to support viral replication and
active infection, when binding sites for receptors encountered on HBV particles are present
and mature enough on the surface of hepatocytes [21].  Therefore, most of the cases, although
small amounts of virus are present in the blood or amniotic fluid, are effectively resolved
after early vaccination in the first hours of life combined with immunoglobulin administration
[21]. This might be also the explanation for the lower risk associated to invasive procedure in
women with low viral load and HBeAg-negative. 
Hepatitis C Virus 
Hepatitis  C  has  common  transmission  routes  as  HIV,  and  therefore  it  can  be
associated with HIV infection  (co-infection).  The mother  to child transmission  can occur
during pregnancy, as has the same likelihood in all trimesters [22]. Usually, the risk of fetal
infection is increased when there is active liver disease, when the viral load is higher than
106/mL or in  women co-infected  with HIV. When viral  load is  less than 105 HCV RNA
copies/mL [23] the chance of vertical transmission is lower, but not inexistent as there are
reported cases with undetectable viremia during pregnancy and fetal transmission [24]. 
A recent systematic review quotes the risk of vertical transmission of 5% in women without
HIV co-infection, increasing to 10% when HIV is associated [25]. 
There is limited data to address the potential risk of vertical transmission in women
with HVC undergoing invasive testing and the current recommendations are based on small
case series.  In a study involving 22 women with hepatitis  C, RNA positive detectable  in
serum in 16 of them, undergoing amniocentesis in the second trimester of pregnancy, there
were no cases of neonatal infection [26]. Also, in a study on 161 cases of maternal HCV,
amniocentesis  did not  appear  to  be an independent  risk factor  for  increased  rate  of  viral
transmission [27].    
Antenatal  diagnostic invasive testing in HCV RNA-positive mothers with high VL
could potentially increase the risk of fetal infection, although there is insufficient data [28].
Women  undergoing  amniocentesis  or  other  invasive  procedure  should  be  counselled
regarding the lack of data and potential risks which cannot be excluded.  
According to American  Association for the Study of Liver  Disease (AASLD) and
Infectious Disease Society of America (IDSA)  the most efficient strategy for reducing the
risk of  HCV transmission  from mother  to  child  is  identifying  and treating  HCV-infected
women before conception [29], as treatment during pregnancy is not recommended due to its
teratogenicity.
Human Immunodeficiency Virus
One  major  success  in  the  management  of  HIV  infected  patients  has  been  the
prevention of mother to child transmission. The Paediatric AIDS Clinical Trials Group 076
demonstrated in 1994 that administering zidovudine in pregnancy and neonatal period could
reduce the chance of vertical transmission by 70% [30]. During natural history of HIV in
pregnancy,  with  no  intervention,  the  risk  of  fetal  infections  is  between  15 to  40% [31],
depending on the presence of  risk factors  such as viral  load,  CD4 cell  count,  obstetrical
factors  like  prematurity,  premature  rupture  of  membranes,  intrapartum  procedures,
breastfeeding. In the early 2000, due to routine antenatal screening for HIV and initiation of
treatment  for  at  least  two  weeks  with  antiretroviral  therapy  (ART),  mother  to  child
transmission rate decreases to 0.5% in patients with VL < 50 c/mL [31]. 
In 2015 the French national prospective multicenter Perinatal Cohort concluded that
no mother to child transmission occurred in women on highly active antiretroviral therapy
(HAART) before pregnancy who delivered with plasma VL < 50 c/mL [32]. Inconsiderate of
the  plasma  viral  load,  the  mother  to  child  transmission  rate  is  0.2%  when  HAART is
commenced before conception, 0.4% in the first trimester, 0.9% in second trimester and 2.2%
in the last trimester [32]. Therefore, viral suppression is critical to decrease the chance of HIV
transmission to the unborn child. The longer a woman is on ART during pregnancy, the better
the  outcomes  due  to  an  increased  likelihood  of  an  undetectable  VL  at  delivery,  thus
preventing  vertical  transmission  [32,  33].  An  overview  of  the  risk  of  mother  to  child
transmission of HIV depending on the maternal status of the infection and viral load during
different stages of pregnancy is provided in Table 2.
Invasive testing in a high-risk pregnancy
Whenever  possible,  cfDNA testing  should  be  offered  in  high-risk  pregnancies  for
aneuploidies, as in singleton pregnancies, the detection rate using cfDNA for trisomy 21 is
99.2%, at a false positive rate of 0.09% [34]. If a prenatal invasive diagnostic test is being
considered,  the  clinician  must  inform the  parents  regarding  potential  risks  related  to  the
procedure. 
In  the  past,  antenatal  invasive  testing  or  intrauterine  procedures  were  routinely
discouraged in HIV-infected pregnant women, due to increased risk of MTCT as puncture of
the  uterine  wall,  placenta  or  umbilical  cord  and eventually  lesions  of  the  fetal  skin  may
increase  the  chance  of  introducing  maternal  blood  into  fetal  compartments,  therefore
increasing the risk of fetal HIV infection [35, 36]. 
In the new setting with highly active antiretroviral therapy (HAART) availability, the
largest  perinatal  HIV cohort study does not show a significantly increased risk of MTCT
when performing amniocentesis [36]. A tendency toward higher rates of vertical transmission
was  noted  in  the  absence  of  treatment  and  with  zidovudine  alone,  or  combination  of
zidovudine and lamivudine [32]. 
According to the British HIV Association antenatal  invasive testing should not be
performed before the HIV status of the woman is known. In a HIV positive pregnant woman,
ideally  an  invasive  diagnostic  procedure  should  be  undertaken  when viral  load  has  been
adequately  suppressed  to  <  50  HIV RNA copies/mL with  combination  of  antiretroviral
therapy (cART) [33]. If not on cART and the invasive testing cannot be postponed until viral
suppression is achieved, the formal recommendation is that cART should be commenced to
include  altegravir  400  mg  two  doses  and  a  single  dose  of  200  mg  nevirapine  to  be
administered 2–4 hours before the Invasive procedure [34]. 
After the procedure, antenatal care should be continued as per local protocol and the
frequency of antenatal visits should not be altered, unless there is a specific reason to do so.
The reviewed studies comparing the mother to child transmission risk for HIV before and
after initiation of highly active antiretroviral therapy are listed in Table 3. 
Treponema Pallidum infection — Congenital Syphilis 
Congenital  syphilis  (CS)  can  occur  in  any  stage  of  maternal  infection  during
pregnancy and can cause preterm birth, stillbirth or perinatal death. In the USA the rate of
primary and secondary syphilis in women is increasing since 2014 and subsequently more
cases of congenital syphilis, despite the World Health Organisation initiative to eliminate CS
by 2015 [43]. 
Congenital  syphilis  occurs  after  transplacental  passage  of  spirochetes  in  pregnant
women who are untreated or inadequately treated, or at the time of delivery through contact
with  infectious  maternal  blood,  secretions,  or  genital  lesions,  causing  various  clinical
manifestations from stillbirth and neonatal death, cutaneous and visceral manifestations, to
asymptomatic infection at birth. The risk of vertical transmission depends on gestational age
(increasing with advancing gestation), on maternal infection stage and whether the treatment
was initiated four weeks prior to delivery. MTCT is highest in untreated maternal primary or
secondary syphilis with a rate of about 60–90%, 40% in early latent syphilis, and less than
10% in late latent syphilis [44, 45]. Early diagnosis and treatment in pregnancy significantly
reduce those risks [46]. Aiming to reduce adverse pregnancy outcomes, routine screening is
recommended in the first trimester of pregnancy and for high-risk women re-testing in the
third trimester. Treatment in the first and second trimester has a greater impact in reducing the
risk of perinatal adverse outcomes compared to treatment in the third trimester of pregnancy
[47]. In a large retrospective study on more than 4000 syphilis infected pregnant women, it
was showed that there were no cases of congenital syphilis in women who initiated treatment
in the first trimester, while those who started the treatment in the third trimester had a higher
risk of stillbirth,  preterm birth  and low birth weight neonates  [48].  For a better  neonatal
outcome treatment should be initiated at least 30 days before delivery. The only efficient and
recommended treatment of syphilis remains Benzathine Penicillin G (BPG) and continuous
fetal  monitoring  is  required  once  the  treatment  is  initiated  to  evaluate  for  the  Jarisch-
Herxheimer reaction,  an acute inflammatory response which can cause preterm labor  and
fetal distress and appears in almost 50% of cases [49–51].  
The fetal  infection can be prenatally suspected after 18 weeks gestation when the
fetus is able to produce an immunologic response with new onset ultrasound signs. The most
common are hepatomegaly, placentomegaly, polyhydramnios, fetal anemia, ascites, hydrops,
or  cardiomegaly.  Although signs  of  fetal  infection  will  manifest  in  utero  after  18  weeks
gestation  in  almost  30%  of  infected  untreated  women,  in  12%  of  cases  the  congenital
infection is not prenatally detected, and the signs are evident only after birth [49].In neonates,
syphilis  infection  can  be  asymptomatic  in  up  to  two-thirds  of  cases  and  if  it  remains
recognised and untreated, in 40–60% of the cases there will be long term sequelae such as
Hutchinson’s teeth, interstitial keratitis, eighth-nerve deafness, neurodevelopmental delay. 
Invasive procedure through amniocentesis and fetal blood sampling are performed in
cases  with  suspected  fetal  syphilis  for  diagnosis  (amniotic  fluid  detection  of  treponema
pallidum)  and  for  therapeutic  purpose  [52,  53].  The  main  haematologic  abnormalities  in
congenital  syphilis  are  fetal  anemia,  thrombocytopenia,  leukopenia,  which also determine
some of the ultrasound findings [54]. Intrauterine fetal blood transfusion by cordocentesis to
correct  fetal  anemia  might  be indicated  at  early gestational  ages when delivery is  not  an
option, in addition to high doses of benzathine penicillin intravenously [55].  
Invasive procedure for genetic testing in women with syphilis has not been studied as
an independent risk factor for vertical transmission, being a method for diagnosis in cases of
suspected fetal infection or it might be indicated as a therapeutic option. 
However, with early detection and appropriate maternal treatment, invasive procedure
did  not  seem to  increase  the  risk  of  MTCT.  This  is  supported  by the  results  of  a  study
involving 11 pregnancies, six women with secondary syphilis and five with latent syphilis.
All cases had normal ultrasound examination and amniocentesis was performed before 20
weeks gestation  in  order  to  determine  the  rate  of  vertical  transmission  and to  show that
transplacental transmission can occur before 18 weeks. Amniotic fluid collected was analysed
and treponema pallidum was present in four cases (36%). After adequate maternal treatment
with  benzathine  penicillin  G  started  before  20  weeks  gestation,  all  neonates  were
seronegative at delivery or at follow-up by 6–12 months of age [53].   
CONCLUSIONS
Based on currently available data, fetal medicine specialists should be aware of the
patient’s infectious status before performing an invasive procedure. For patients with hepatitis
B infection, it is important to know the HBeAg-status and HBV DNA levels and for those
patients with high viral load, antiviral therapy (Tenofovir) for a few weeks may be needed to
reduce the viral load prior to the invasive procedure.
In women positive  for HCV, the viral  load and HIV status should be assessed to
establish  the  risk  of  vertical  transmission;  while  for  patients  with  HIV,  highly  active
antiretroviral  therapy administration and low viral  load are predictive for reduced vertical
transmission even after performing an invasive procedure. In all cases invasive procedure
should be replaced by non-invasive prenatal testing if this is a feasible alternative and when
invasive testing is indeed required, transplacental passage should be avoided. Figure 1 gives
an overview of the risk factors, rate of vertical  transmission after invasive procedure and
preventive measures in chronic viral infections. There is a need to better understand these
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Table 1. Reviewed studies comparing the MTCT in pregnant women with chronic hepatitis B
with  and  without  the  invasive  procedure  (amniocentesis)  performed  during  pregnancy;
HBeAg+ — positive hepatitis B e-antigen; c/mL — copies/mL; m — months; y — years;










et  al. 1994
[14]
15 2 Not reported 0%
Ko  et  al. 67 19 Not reported 1/35 (2.9%) at birth 2/65 (3.1%) at birth
1994 [15] 3/32 (9.4%) at  3m–
5y all  in  cases  with
HBeAg +











Yi  W  et  al.
2014 [10]




50% in high VL
2.5%
4.5% in high VL
Han  et  al.
2019 [12]
143 49 37 > 7.0 log10
c/mL
11/143  (7.7%)  at
birth
4 (2.8%) at 7–12 m
all in HBeAg + 
34/605  (5.6%)  at
birth
3 (0.5%) at 7–12 m
Table 2.  The risk of mother to child transmission of HIV depending on the maternal status of
the  infection  and  viral  load  during  different  stages  of  pregnancy;  ART — antiretroviral
therapy; c/mL — copies/mL; MTCT — mother-to-child-transmission, VL — viral load
HIV positive pregnant patient Risk of
MTCT
No treatment 25%
On ART with VL < 50 c/mL before conception 0.0%
On ART before conception regardless VL 0.2%
On ART in 1st trimester, regardless VL 0.4%
On ART in 2nd trimester, regardless VL 0.9%
On ART in 3rd trimester, regardless VL 2.2%
On ART with VL < 50 c/mL, regardless the start 0.5%
Table  3. The reviewed studies  comparing  the  mother  to  child  transmission  risk for  HIV
before and after initiation of highly active antiretroviral therapy; HAART — highly active
antiretroviral  therapy;  MTCT —  mother-to-child  transmission;  CVS  —  chorionic  villus
sampling
Study Invasive procedure No invasive procedure
Pre HAART
Mandelbrot et al 1996 [39] Amniocentesis, amnioscopy
MTCT 36% MTCT 18%









Floridia et al 2016 [41] 75 amniocentesis, 12 CVS
MTCT 2.3% (2/88)
86 negative — on HAART
Simoes et al 2013 [42] 27 amniocenteses, 20 on
HAART
MTCT 1/7 (14%) from
cases without HAART
Mandelbrot et al 2009 [37] MTCT 0% on HAART
Figure 1. Risk factors, rate of vertical transmission after invasive procedure and preventive
measures in chronic viral infections 
